Protagenic Therapeutics I... (PTIX)
Protagenic Therapeutics Statistics
Share Statistics
Protagenic Therapeutics has 7.53M shares outstanding. The number of shares has increased by 62.65% in one year.
| Shares Outstanding | 7.53M |
| Shares Change (YoY) | 62.65% |
| Shares Change (QoQ) | 1.37% |
| Owned by Institutions (%) | 14.16% |
| Shares Floating | 6.52M |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 89.12K, so 1.23% of the outstanding shares have been sold short.
| Short Interest | 89.12K |
| Short % of Shares Out | 1.23% |
| Short % of Float | 1.42% |
| Short Ratio (days to cover) | 1.33 |
Valuation Ratios
The PE ratio is -0.43 and the forward PE ratio is -0.82. Protagenic Therapeutics's PEG ratio is 0.25.
| PE Ratio | -0.43 |
| Forward PE | -0.82 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 2.37 |
| P/FCF Ratio | -0.57 |
| PEG Ratio | 0.25 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Protagenic Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2, with a Debt / Equity ratio of 0.
| Current Ratio | 2 |
| Quick Ratio | 2 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-5.53M |
| Employee Count | 1 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -77.02% in the last 52 weeks. The beta is 0.35, so Protagenic Therapeutics's price volatility has been higher than the market average.
| Beta | 0.35 |
| 52-Week Price Change | -77.02% |
| 50-Day Moving Average | 0.3 |
| 200-Day Moving Average | 0.56 |
| Relative Strength Index (RSI) | 61.22 |
| Average Volume (20 Days) | 5.31M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -5.7M |
| Net Income | -5.53M |
| EBITDA | -5.7M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.13 |
Balance Sheet
The company has 1.84M in cash and 0 in debt, giving a net cash position of 1.84M.
| Cash & Cash Equivalents | 1.84M |
| Total Debt | 0 |
| Net Cash | 1.84M |
| Retained Earnings | -36.3M |
| Total Assets | 1.51M |
| Working Capital | 633.39K |
Cash Flow
In the last 12 months, operating cash flow was -4.22M and capital expenditures 0, giving a free cash flow of -4.22M.
| Operating Cash Flow | -4.22M |
| Capital Expenditures | 0 |
| Free Cash Flow | -4.22M |
| FCF Per Share | -0.86 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PTIX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for PTIX.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Mar 23, 2023. It was a backward split with a ratio of 1:4.
| Last Split Date | Mar 23, 2023 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | -41.65 |
| Piotroski F-Score | 3 |